Summarily, our results show that Aβ treatment leads to a significant decrease in PSA-NCAM, ST8Sia4, and UDP-E expression, linking Aβ to impaired polysialylation and synaptic dysfunction in AD. Here, NCAM1 is linked to Alzheimer disease.